Searched for: in-biosketch:true
person:rodrie20
Monitoring outcomes of the first human whole eye allotransplant
Dedania, Vaidehi S; Shah, Alay R; Chinta, Sachin R; Tran, David L; Brodie, Scott E; Gelb, Bruce E; Ceradini, Daniel J; Rodriguez, Eduardo D
PURPOSE/OBJECTIVE:To describe the first successful whole eye transplantation (WET) in a human, performed with concurrent partial face transplantation, and to characterize postoperative outcomes. DESIGN/METHODS:Case report. PARTICIPANT/METHODS:A 46-year-old male with severe facial and ocular deficits following high-voltage electrical injury, including left eye enucleation and extensive soft tissue and aesthetic deformities. METHODS:Comprehensive preoperative evaluation, precise microsurgical techniques including vascular anastomosis and optic nerve coaptation, and serial postoperative assessments with optical coherence tomography (OCT), fluorescein angiography (FA), electroretinography (ERG), and visual evoked potentials (VEP). MAIN OUTCOME MEASURES/METHODS:Sustained globe viability, vascular perfusion, retinal structural integrity, and electrophysiological function. RESULTS:The transplanted globe demonstrated robust vascular perfusion and structural preservation over 12 months. Outer retinal function was maintained, as indicated by ERG, despite retinal nerve fiber layer loss and optic nerve transection. VEP confirmed absence of visual perception. The procedure achieved substantial aesthetic restoration. CONCLUSIONS:This study establishes the feasibility of WET in humans, with sustained globe viability and preserved outer retinal function. These findings serve as a critical step toward future exploration of ocular transplantation.
PMID: 41764690
ISSN: 1573-2622
CID: 6008102
Preservation Strategies for Vascularized Composite Allotransplantation: An Updated Systematic Review of a Rapidly Expanding Field
Njessi, Pharel; Barbat, Pierre; Piul, Rabbani S; Pisani, Didier F; Camuzard, Olivier; Sicard, Antoine; Rodriguez, Eduardo; Lupon, Elise
BACKGROUND:Composite allotransplantation has become a viable reconstructive option for selected patients, but preservation remains a major barrier to broader clinical application. Static cold storage is the current gold standard, yet ischemia reperfusion injury and limited preservation times restrict its effectiveness. Recent advances in machine perfusion and subzero nonfreezing storage (or supercooling) have prompted renewed interest in optimizing graft viability. METHODS:Following PRISMA guidelines, we systematically searched PubMed, EMBASE, and Cochrane, covering studies published from June 2022 to August 2025 for studies on ex vivo preservation of vascularized composite allotransplantations. Eligible articles included original studies in English evaluating postharvest, pretransplant preservation strategies. Data extracted were study design, preservation methods, perfusates, and primary outcomes. Risk of bias was assessed using SYRCLE for animal studies and Joanna Briggs Institute for human/cadaver studies. RESULTS:Seventeen studies met the inclusion criteria: 1 on static cold storage, 13 on machine perfusion, and 3 on supercooling. Static cold storage research has declined, with the only recent study investigating subnormothermic machine perfusion as a recovery adjunct. Machine perfusion studies focused on the optimization of perfusion parameters, perfusate composition, and circuit design. Red blood cell-based perfusates remained common, but alternative oxygen carriers such as polymerized hemoglobin-based oxygen carrier-201 and dextran oxygen microcarriers showed promise despite edema-related challenges. Supercooling studies demonstrated the feasibility of multiday preservation in rodent and porcine models. Overall, risk of bias was high or unclear across animal studies, mainly due to selection and performance bias, whereas the single human ex vivo study showed low risk of bias. CONCLUSIONS:The field of vascularized composite allograft preservation is expanding rapidly, with a combination of static and dynamic techniques emerging as a promising option to extend graft viability beyond the current limits. However, translation to clinical setting remains limited by small preclinical studies, methodological heterogeneity, and the paucity of functional endpoints. Standardized protocols, robust large-animal models, and eventual human feasibility trials are needed to establish clinically applicable preservation strategies.
PMID: 41719079
ISSN: 1536-3708
CID: 6005342
Using Machine Learning as a Seroma Risk Assessment Tool in Prepectoral Breast Reconstruction
Chinta, Sachin R; Lisk, Rebecca; Shah, Alay R; Boyd, Carter J; Hemal, Kshipra; Sorenson, Thomas J; Choi, Mihye; Rodriguez, Eduardo D; Cohen, Oriana D; Karp, Nolan S
BACKGROUND/UNASSIGNED:This study aimed to develop a machine learning model to predict seroma risk following prepectoral breast reconstruction. METHODS/UNASSIGNED:-nearest neighbors, decision tree, and random forest. RESULTS/UNASSIGNED:Chart review identified 318 breasts that underwent prepectoral reconstruction, with a seroma rate of 25.58%. Univariate analysis found that body mass index, mastectomy specimen weight, hypertension, neoadjuvant chemotherapy, and skin-sparing mastectomy were positively associated with seroma. Method 1 identified the decision tree to have the highest accuracy (0.81) and area under the receiver operating characteristic curve (0.81). Method 2 improved model performance. The random forest achieved the best results, with an accuracy of 0.81 and an area under the receiver operating characteristic curve of 0.83. A web application was then created using the random forest model to provide real-time seroma risk predictions. CONCLUSIONS/UNASSIGNED:Machine learning models offer a valuable tool for improving clinical decision-making by accurately predicting patient-specific seroma risk in breast reconstruction. Our models outperformed traditional methods in identifying high-risk patients, allowing for tailored surgical techniques and intensified follow-up care.
PMCID:12834434
PMID: 41602846
ISSN: 2169-7574
CID: 6003412
100 most-cited publications in vascularized composite allotransplantation
Njessi, Pharel; Boyd, Carter J; Petruzzo, Palmina; Camuzard, Olivier; Sicard, Antoine; Kantar, Rami; Rodriguez, Eduardo; Lupon, Elise
BACKGROUND/UNASSIGNED:Citation analysis is a useful bibliometric tool to identify impactful publications and trace the evolution of a specialty or a technique. In the past three decades, the research on vascularized composite allotransplantation (VCA) has grown exponentially but very few studies have examined the most influential papers in this field. METHODS/UNASSIGNED:The Web of Science Core Collection database was searched for articles published from inception to August 4th, 2025. Titles, full authors' names, years of publication, source journals, regions of origin, and numbers of citations were recorded. VCA anatomical location, main topics, and citation density were determined. Articles were ranked based on number of citations and citation density; they were then categorized based on methodology, study design, and main topic. RESULTS/UNASSIGNED: = 51) were classified as level 4. DISCUSSION/UNASSIGNED:This list of the top 100 most-cited articles highlights seminal and influential papers in VCA. It also demonstrates the relative novelty of this field with ongoing efforts in immunological research to allow its further expansion. The present study provides an understanding of VCA evolution while directing future clinical and preclinical studies.
PMCID:12957187
PMID: 41789363
ISSN: 2813-2440
CID: 6009242
Logistical, Ethical, and Technical Considerations in the World's First Face and Whole Eye Transplantation
Chinta, Sachin R; Tran, David L; Shah, Alay R; Ceradini, Daniel J; Dedania, Vaidehi S; Gelb, Bruce E; Cohen, Oriana D; Flores, Roberto L; Levine, Jamie P; Saadeh, Pierre B; Staffenberg, David A; Rojas, Allison C; Rodriguez, Eduardo D
BACKGROUND:Whole eye transplantation (WET) has long been looked to as a potential solution for the aesthetic and functional deficits caused by severe ocular pathology and trauma. Here, we describe the first successful combined face and whole eye transplantation (FT/WET), highlighting the logistical, ethical, and technical considerations that enabled this milestone. METHODS:A 46-year-old male with severe facial and ocular deficits underwent multidisciplinary evaluation and was deemed a candidate for FT/WET. Subsequently, a surgical algorithm was developed through rigorous preoperative planning and team based surgical simulations. This process focused on techniques that would allow for efficient graft procurement and inset, while simultaneously limiting trauma to the globe and its adnexa. RESULTS:Longitudinal monitoring demonstrated maintained graft viability throughout the postoperative period. Fluorescein angiography and ICG angiography confirmed robust retinal and choroidal perfusion. Diffusion-weighted MRI revealed structural preservation of the optic tracts, despite inner retinal atrophy. The patient has also experienced significant improvement in facial aesthetics and functionality with no episodes of graft rejection to date. CONCLUSIONS:This case demonstrates the feasibility of addressing deficits once deemed irreparable through advanced surgical techniques, preoperative planning, and multidisciplinary collaboration. Although functional vision recovery has not been observed, this innovation expands the reconstructive options available for patients with severe facial and ocular deficits, paving the way for future advancements in vascularized composite allotransplantation.
PMID: 41467696
ISSN: 1529-4242
CID: 5985642
Surgical Approach to Full Soft Tissue Face Allograft Procurement for Vascularized Composite Allotransplantation
Lupon, Elise; Segrera, Sergio A; Perraudin, Tanguy; Narayanan, Anandhini D; Gursky, Alexis K; Wyatt, Hailey P; Rodriguez, Eduardo D
Full facial vascularized composite allotransplantation (VCA) offers a reconstructive option for patients with severe facial disfigurement who cannot be treated with conventional methods. This article details a surgical protocol for donor procurement of a full facial allograft, focusing on soft tissue with limited bony harvest restricted to the nasal framework, and emphasizes key anatomical landmarks and technical considerations for safe and efficient harvest. The procedure involves dissection of the entire facial soft tissues while preserving the external carotid artery, internal jugular veins and subsequent thyro-linguofacial, and branches of the facial and maxillary nerves to maximize pedicle length for later neurorrhaphy. The protocol describes systematic exposure of the vascular pedicles at their origin in the neck, subperiosteal elevation of the scalp, identification and division of the supraorbital and infraorbital nerves, and preparation of the facial nerve at its root to achieve optimal length. Strategies to minimize ischemia time and ensure allograft integrity are highlighted. This article provides a comprehensive visual guide to the procurement phase of a full soft tissue face allograft and aims to standardize the technique for research application and surgical training in advanced vascularized composite allotransplantation.
PMID: 41554000
ISSN: 1940-087x
CID: 5988142
Pretreatments of Ex Vivo Vascularized Composite Allografts: A Scoping Review
Baker, Caroline E; Stead, Thor S; Pullmann, Dominika; Shah, Alay R; Chinta, Sachin; Tran, David L; Brydges, Hilliard T; Laspro, Matteo; Gelb, Bruce E; Rodriguez, Eduardo D; Rabbani, Piul S
PURPOSE/OBJECTIVE:The various physiological profiles comprising vascularized composite allografts (VCAs) pose unique challenges to preservation. Minimizing ischemia, reperfusion injury, and rejection remains a primary focus of graft pretreatments (PTs). Currently, the gold standard PT consists of flushing the graft and placing it in static cold storage in the University of Wisconsin solution. With this method, graft viability is limited to 4 to 6 hours. Prolonging this time limit will increase donor allocation radius, access to care, and positive patient outcomes. We aimed to evaluate novel PTs that could potentially enhance and lengthen VCA viability. METHODS:Following PRISMA (Preferred Reporting Items for Systematic reviews and Meta-Analyses) guidelines, we conducted a comprehensive literature search of EMBASE, Cochrane, and PubMed. Studies had to be published prior to June 15, 2022. PTs had to target cell physiology, rather than immunogenicity. We extracted data including study design, PT details, evaluation metrics, and outcomes. RESULTS:We identified 13 studies, categorized into 3 groups: solution-based alterations to the gold standard, ex vivo perfusion, and other novel techniques. The incorporation of hydrogen sulfide and Perfadex as solutions in the gold standard protocol demonstrated a 6-day delay in rejection and limited reperfusion injury markers, respectively. In an ex vivo perfusion study, after 24 hours of PT and 12 hours posttransplant, VCA muscle contractility remained close to normal. The gold standard PT did not demonstrate the same success. However, graft weight gain, up to 50% of baseline among the reviewed articles, is a prominent adverse effect of perfusion. Another technique, cryopreservation, displayed 90% graft failure by venous thrombosis, despite high free graft viability following 2 weeks of storage. CONCLUSIONS:This study of PT modalities found a variety of encouraging preservation techniques for grafts with high levels of tissue diversity. Ex vivo perfusion dominated PT innovation with promising results in preserving the viability and functionality of muscle, which is central to the restoration of movement. Future studies are necessary to evaluate long-term graft outcomes and to optimize PT protocols for extended preservation times to ensure clinical relevance.
PMID: 40532232
ISSN: 1536-3708
CID: 5871082
Swallowing Function After Pioneering Partial Face and Whole Eye Transplant: Clinical Insights
Lico, Margaret; Hanley, Kaitlin; Shah, Alay; Chinta, Sachin; Ceradini, Daniel J; Rodriguez, Eduardo D
PURPOSE/UNASSIGNED:There is limited literature reporting swallowing outcomes in the pre- and postoperative period for patients undergoing facial transplantation. This case report aims to utilize a combination of objective and patient-reported outcome measures to highlight swallowing improvements following the world's first face with whole-eye transplantation. METHOD/UNASSIGNED:Outcome measures in jaw range of motion, anterior containment, texture progression, airway protection, and pharyngeal swallow function were collected pretransplantation by two speech-language pathologists (SLPs) and at multiple postoperative visits after the procedure was completed. Specific outcome measures included the Gothenburg Trismus Questionnaire, Maximal Incisor Opening, Modified Teachers Drooling Scale, Functional Oral Intake Scale, Eating Assessment Tool-10, The Penetration-Aspiration Scale, and the Modified Barium Swallow Study Impairment Profile. Measures were then compared over a 1-year time period to assess changes in swallow function. RESULTS/UNASSIGNED:Improvements in jaw range of motion, anterior containment, and airway protection were observed. The patient's stated goal of returning to full PO diet following face transplant was achieved within 1 year. CONCLUSIONS/UNASSIGNED:Swallowing and trismus outcome measures are an important tool for monitoring progress along a patient's recovery journey, especially following unique procedures such as face transplantation. Based on this single patient case study, facial transplantation can lead to improvements in both objective and patient-reported outcomes. Future goals for research should continue to explore this unique population due to the limited literature available for SLPs, as well as include development of valid and reliable assessment tools specific to the face transplantation population.
PMID: 40403408
ISSN: 1558-9110
CID: 5853442
Vascularized Composite Allotransplantation of the Uterus: A Systematic Review of Eligibility Criteria
Diaz, Allison L; Laspro, Matteo; Chinta, Sachin; Shah, Alay; Rodriguez, Eduardo D
BACKGROUND:Uterus transplantation (UTx) is the sole clinical treatment for patients with a diagnosis of uterine infertility factor to experience gestation and delivery. Following UTx, candidates who have been largely healthy must agree to extensively interface with the healthcare system and practice strict adherence to an immunosuppressive regimen to protect the allograft until delivery of a live birth. Aside from the risks associated with immunosuppression, UTx recipients often face complicated pregnancies, with a possibility of pregnancy loss and allograft failure. Therefore, appropriate recipient eligibility criteria are central to transplantation success. The objective of this study is to investigate eligibility criteria reported by UTx programs globally. METHODS:A systematic review of UTx literature was conducted according to Preferred Reporting Items for Systematic Review and Meta-Analyses guidelines, using PubMed, Cochrane, Ovid/MEDLINE, and Scopus. ClinicalTrials.gov entries and program websites were queried for eligibility criteria as well. RESULTS:Two hundred ninety-six studies were identified, 79 of which were included in the final review. Twenty-one clinical trials and 6 patient-facing websites were included. Most reported eligibility criteria included females of reproductive age, excellent in vitro fertilization candidacy, psychological stability, absence of systemic infection, and willingness to comply with all treatment protocols. The importance of factors such as social support and recipient relationship with their partner varied between centers. CONCLUSION/CONCLUSIONS:Although consensus exists across certain eligibility criteria, the importance of other criteria presents greater ambiguity across centers. As UTx programs expand, and more patients gain access to the procedure, the evolution of eligibility criteria must be documented to optimize best practices across centers.
PMID: 40272522
ISSN: 1536-3708
CID: 5830522
Immunologic Pretreatment of Donor Tissue in Vascularized Composite Allotransplantation: A Systematic Review
Stead, Thor S; Laspro, Matteo; Brydges, Hilliard T; Chinta, Sachin R; Shah, Alay R; Rabbani, Piul S; Gelb, Bruce E; Rodriguez, Eduardo D
BACKGROUND:Vascularized composite allotransplantation (VCA) holds significant promise for patients with complex structural defects, providing solutions unattainable through traditional methods. Despite technical successes, graft rejection and ischemia-reperfusion injury (IRI) present major challenges, with high rejection rates even under modern immunosuppression protocols. This review synthesizes current literature on immunologic pretreatments (IPTs) designed to mitigate these issues, focusing on interventions applied to donor tissues between procurement and transplantation. METHODS:A systematic review following Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines identified 11 relevant studies, categorizing IPTs into donor tissue modification (DTM), deoxygenated perfusate, and oxygenation methods. RESULTS:DTM, the most common IPT method, shows promise in reducing immunogenicity and prolonging graft survival, primarily through techniques such as recipient bone marrow-derived cell conditioning and MHC-I knockdown using small interfering RNA (siRNA). Deoxygenated perfusate studies highlighted mitomycin C's potential in reducing immune response and extending graft viability. Oxygenation methods, aimed at minimizing IRIs, utilized perfusion techniques to maintain graft viability ex vivo. CONCLUSIONS:Although IPTs for extending graft survival have seen moderate clinical translation, those targeting immunogenicity remain largely experimental. This review underscores the potential of these IPT modalities to improve VCA outcomes by reducing rejection and IRIs. However, it also highlights the need for further research, particularly multi-center clinical trials, to validate these techniques for broader clinical adoption. This comprehensive synthesis aims to guide future studies and enhance clinical strategies for VCA, ultimately improving patient outcomes.
PMID: 40113491
ISSN: 1873-2623
CID: 5813652